Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, Suven Life Sciences has informed that the Board of Directors of the company, at its meeting held today i.e. January 29, 2026, has considered and approved the following along with other business matters: Allotment of 44,77,612 Equity Shares of the Company on preferential basis upon conversion 44,77,612 fully paid warrants; Resignation of Shrenik Soni, Company Secretary & Compliance Officer (KMP) of the Company; and appointment of Sangeetha Laxmi Kandari (ICSI M. No. A40736) as Company Secretary & Compliance Officer of the Company (Key Managerial Personnel).
The above information is a part of company’s filings submitted to BSE.
